Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Common Equity (2016 - 2025)

Historic Common Equity for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $4.9 million.

  • Lexaria Bioscience's Common Equity fell 4770.21% to $4.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $4.9 million, marking a year-over-year decrease of 4770.21%. This contributed to the annual value of $3.0 million for FY2025, which is 6096.52% down from last year.
  • Lexaria Bioscience's Common Equity amounted to $4.9 million in Q4 2025, which was down 4770.21% from $3.0 million recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Common Equity high stood at $13.1 million for Q3 2021, and its period low was $2.7 million during Q3 2023.
  • In the last 5 years, Lexaria Bioscience's Common Equity had a median value of $7.4 million in 2022 and averaged $7.5 million.
  • Per our database at Business Quant, Lexaria Bioscience's Common Equity skyrocketed by 52978.93% in 2021 and then tumbled by 6488.59% in 2023.
  • Over the past 5 years, Lexaria Bioscience's Common Equity (Quarter) stood at $11.5 million in 2021, then tumbled by 45.82% to $6.2 million in 2022, then plummeted by 41.63% to $3.6 million in 2023, then skyrocketed by 159.02% to $9.4 million in 2024, then plummeted by 47.7% to $4.9 million in 2025.
  • Its last three reported values are $4.9 million in Q4 2025, $3.0 million for Q3 2025, and $5.6 million during Q2 2025.